KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Raw Materials (2017 - 2021)

Aquestive Therapeutics has reported Raw Materials over the past 5 years, most recently at $833000.0 for Q1 2021.

  • For Q1 2021, Raw Materials fell 35.18% year-over-year to $833000.0; the TTM value through Mar 2021 reached $833000.0, down 35.18%, while the annual FY2020 figure was $789000.0, 36.58% down from the prior year.
  • Raw Materials for Q1 2021 was $833000.0 at Aquestive Therapeutics, up from $789000.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $1.4 million in Q1 2019 and troughed at $725000.0 in Q4 2017.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2020 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: soared 76.97% in 2018 and later tumbled 36.58% in 2020.
  • Year by year, Raw Materials stood at $725000.0 in 2017, then skyrocketed by 76.97% to $1.3 million in 2018, then decreased by 3.04% to $1.2 million in 2019, then crashed by 36.58% to $789000.0 in 2020, then increased by 5.58% to $833000.0 in 2021.
  • Business Quant data shows Raw Materials for AQST at $833000.0 in Q1 2021, $789000.0 in Q4 2020, and $1.2 million in Q3 2020.